Study results from Sichuan University in the area of ovarian cancer published
2009 AUG 3 - (NewsRx.com) -- "ARLTS1 has been identified in chromosome 13q14 as a tumor suppressor gene of the adenosine diphosphate-ribosylation factor firmly with pro-apoptotic characteristics. The ARLTS1 mutation Trp 149Stop and Cys148Arg have been shown to be associated with familial cancers, but limited information is available regarding the impact of ARLTS1 variants on familial ovarian cancer (OC)," scientists in Chengdu, People's Republic of China report. "The aim of this study was to evaluate the ARLTS1 genetic variants associated with familial OC risk in China. We genotyped 85 OC patients with family ovarian/breast history, 80 sporadic OC patients, and 120 controls from general population by denaturing high-performance liquid chromatography screening analysis followed by direct sequencing of the conspicuous polymerase chain reaction products. ARLTS1 Cys148Arg revealed a significant association with an increased risk of familial OC compared with both sporadic cases and controls in a dose-dependent manner (P 0.0031 and 0.012, respectively). In the clinical-pathological study, Our results support previous data in demonstrating that familial OC was associated with younger age at diagnosis (49.7 years vs 53.3 years; P = 0.0 14), higher proportion of tumors of advanced stages (81.2% vs 67.5%; P = 0.033), and higher rates of serous adenocarcinomas (76.4% vs 53.8%; P = 0.028) compared with sporadic OC cases. To investigate the association between genetic variants of ARLTS1 and the clinical-pathological characteristics of familial OC, we identified a significantly higher proportion of serous adenocarcinoma (55/67, 82.1%) and higher rates of advanced stage tumors (88.1% vs 55.6%; P = 0.004) in ARLTS1 Cys148Arg carriers," wrote X.Y. Yang and colleagues, Sichuan University. The researchers concluded: "We showed a significantly increased risk of familial OC for ARLTSI Cys148Arg variant, which indicate that ARLTS1 may play a role in familial OC.." Yang and colleagues published their study in International Journal of Gynecological Cancer (Association of the ARLTS1 Variants With Familial Ovarian Cancer Risk in China. International Journal of Gynecological Cancer, 2009;19(4):585-590). For additional information, contact Z.L. Peng, Sichuan University, Dept. of Obstetrics & Gynecology, W China University Hospital 2, Chengdu 610041, Sichuan, People's Republic of China. The publisher's contact information for the International Journal of Gynecological Cancer is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: People's Republic of China, Chengdu, Adenosine, Diagnosis, Diagnostics, Drugs, Enzyme Research, Familial Cancer, Genetics, Gynecology, Hereditary, Liquid Chromatography, Oncology, Ovarian Cancer, Ovarian Carcinoma, Pharmaceuticals, Polymerase, Therapy, Treatment, Tumor Suppression, Women's Health, Sichuan University. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
